Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy

Journal of Colloid and Interface Science

Volumn 451, Issue , 2015, Pages 198-211

  Parhi, Priyambada ^a   Sahoo, Sanjeeb Kumar ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Nanoparticles; Nanotheranostics; Quantum dots; Rapamycin; Trastuzumab

Indexed keywords

ANTIBODIES; CELL CULTURE; CELL DEATH; CELL SIGNALING; CELLS; DIAGNOSIS; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL IMAGING; MOBILE SECURITY; MONOCLONAL ANTIBODIES; NANOCRYSTALS; NANOPARTICLES; ONCOLOGY; SEMICONDUCTOR QUANTUM DOTS;

FUNCTIONALIZED LIPIDS; HUMAN EPIDERMAL GROWTH FACTOR; HUMANIZED MONOCLONAL ANTIBODY; NANOTHERANOSTICS; RAPAMYCIN; TARGETED CANCER THERAPY; TARGETED DRUG DELIVERY; TRASTUZUMAB;

DRUG THERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCEROL OLEATE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NANOCARRIER; PROTEIN; PROTEIN 70S6K1; PROTEIN BCL 2; PROTEIN KINASE B; QUANTUM DOT; RAPAMYCIN; STAT3 PROTEIN; TOCOFERSOLAN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; LIPID; NANOPARTICLE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL DEATH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOWN REGULATION; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; NANOTHERANOSTIC; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROPHOTOMETER; UPTAKE ASSAY; WESTERN BLOTTING; BREAST; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPIDS; NANOPARTICLES; QUANTUM DOTS; RECEPTOR, ERBB-2; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRASTUZUMAB;

EID: 84927739374     PISSN: 00219797     EISSN: 10957103     Source Type: Journal    
DOI: 10.1016/j.jcis.2015.03.049     Document Type: Article

References (60)

1. Parveen S., Sahoo S.K. J. Drug Target. 2008, 16:108-123.
2. Misra R., Acharya S., Sahoo S.K. Drug Discov. Today 2010, 15:842-850.
3. Sahoo S.K., Labhasetwar V. Drug Discov. Today 2003, 8:1112-1120.
4. Sahoo S.K., Parveen S., Panda J.J. Nanomedicine 2007, 3:20-31.
5. Parveen S., Misra R., Sahoo S.K. Nanomedicine 2011, 8:147-166.
6. Smith A.M., Duan H., Mohs A.M., Nie S. Adv. Drug Deliv. Rev. 2008, 60:1226-1240.
7. Wu W., Aiello M., Zhou T., Berliner A., Banerjee P., Zhou S. Biomaterials 2010, 31:3023-3031.
8. Hidalgo M., Rowinsky E.K. Oncogene 2000, 19:6680-6686.
9. Noh W.C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., Mills G.B., Hung M.C., Meric-Bernstam F. Clin. Cancer Res. 2004, 10:1013-1023.
10. Bjornsti M.A., Houghton P.J. Nat. Rev. Cancer 2004, 4:335-348.
11. Easton J.B., Houghton P.J. Oncogene 2006, 25:6436-6446.
12. Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., Germain G.S., Abraham R.T., Houghton P.J. Cancer Res. 1999, 59:886-894.
13. Seufferlein T., Rozengurt E. Cancer Res. 1996, 56:3895-3897.
14. Simamora P., Alvarez J.M., Yalkowsky S.H. Int. J. Pharm. 2001, 213:25-29.
15. Acharya S., Dilnawaz F., Sahoo S.K. Biomaterials 2009, 30:5737-5750.
16. Bisht S., Feldmann G., Koorstra J.B., Mullendore M., Alvarez H., Karikari C., Rudek M.A., Lee C.K., Maitra A., Maitra A. Mol. Cancer Ther. 2008, 7:3878-3888.
17. Zou J., Zhang X., Yang H., Zhu Y., Ma H., Wang S. Ann. Vasc. Surg. 2011, 25:538-546.
18. Miller A.D. J. Drug Deliv. 2013, 2013:165981.
19. Puri A., Loomis K., Smith B., Lee J.H., Yavlovich A., Heldman E., Blumenthal R. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26:523-580.
20. Barauskas J., Cervin C., Jankunec M., Spandyreva M., Ribokaite K., Tiberg F., Johnsson M. Int. J. Pharm. 2010, 391:284-291.
21. Boyd B.J., Whittaker D.V., Khoo S.M., Davey G. Int. J. Pharm. 2006, 309:218-226.
22. Spicer P., Hayden K., Lynch M., Ofori-Boateng A., Burns J. Langmuir 2001, 17(19):5748-5756.
23. Dilnawaz F., Singh A., Mewar S., Sharma U., Jagannathan N.R., Sahoo S.K. Biomaterials 2011, 33:2936-2951.
24. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Biomaterials 2010, 31:3694-3706.
25. Ganguly S., Dash A.K. Int. J. Pharm. 2004, 276:83-92.
26. Choi W.I., Lee J.H., Kim J.Y., Heo S.U., Jeong Y.Y., Kim Y.H., Tae G. Nanomedicine 2014, 11:359-368.
27. Das M., Mohanty C., Sahoo S.K. Exp. Opin. Drug Deliv. 2009, 6:285-304.
28. Gao X., Yang L., Petros J.A., Marshall F.F., Simons J.W., Nie S. Curr. Opin. Biotechnol. 2005, 16:63-72.
29. Xing Y., Rao J. Cancer Biomark 2008, 4:307-319.
30. Nehilla B.J., Allen P.G., Desai T.A. ACS Nano 2008, 2:538-544.
31. Pan J., Feng S.S. Biomaterials 2009, 30:1176-1183.
32. Zhang Z., Huey S. Biomaterials 2007, 28:1889-1899.
33. Vandana M., Sahoo S.K. Mol. Pharm. 2012, 9:2828-2843.
34. Mohanty C., Sahoo S.K. Biomaterials 2010, 31:6597-6611.
35. Das M., Duan W., Sahoo S.K. Nanomedicine 2015, 11:379-389.
36. Panyam J., Sahoo S.K., Prabha S., Bargar T., Labhasetwar V. Int. J. Pharm. 2003, 262:1-11.
37. Vega F., Medeiros L.J., Leventaki V., Atwell C., Cho-Vega J.H., Tian L., Claret F.X., Rassidakis G.Z. Cancer Res. 2006, 66:6589-6597.
38. Misra R., Das M., Sahoo B.S., Sahoo S.K. Int. J. Pharm. 2014, 475:372-384.
39. Gilmore K., Wilson M. Cytometry 1999, 36:355-358.
40. Green D.R., Reed J.C. Science 1998, 281:1309-1312.
41. Ivascu A., Kubbies M. J. Biomol. Screen 2006, 11:922-932.
42. Hong S.M., Park C.W., Cha H.J., Kwon J.H., Yun Y.S., Lee N.G., Kim D.G., Nam H.G., Choi K.Y. Clin. Exp. Metast. 2012, 30:177-187.
43. Kim S.H., Zukowski K., Novak R.F. Anticancer Res. 2009, 29:1143-1150.
44. Muthukkumar S., Ramesh T.M., Bondada S. Transplantation 1995, 60:264-270.
45. Muthu M.S., Leong D.T., Mei L., Feng S.S. Theranostics 2014, 4:660-677.
46. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. Nat. Biotechnol. 2004, 22:969-976.
47. Savla R., Taratula O., Garbuzenko O., Minko T. J. Control Release 2011, 153:16-22.
48. Gaur U., Sahoo S.K., De T.K., Ghosh P.C., Maitra A., Ghosh P.K. Int. J. Pharm. 2000, 202:1-10.
49. Yu S.S., Lau C.M., Thomas S.N., Jerome W.G., Maron D.J., Dickerson J.H., Hubbell J.A., Giorgio T.D. Int. J. Nanomed. 2012, 7:799-813.
50. Fang C., Bhattarai N., Sun C., Zhang M. Small 2009, 5:1637-1641.
51. Das M., Dilnawaz F., Sahoo S.K. Nanomedicine (London) 2011, 6:489-507.
52. Tokuda Y. Int. J. Clin. Oncol. 2003, 8:224-229.
53. zum Buschenfelde C.M., Hermann C., Schmidt B., Peschel C., Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002, 62:2244-2247.
54. Steinhauser I., Spankuch B., Strebhardt K., Langer K. Biomaterials 2006, 27:4975-4983.
55. Averous J., Proud C.G. Oncogene 2006, 25:6423-6435.
56. Reddy M.K., Vasir J.K., Sahoo S.K., Jain T.K., Yallapu M.M., Labhasetwar V. Circ. Cardiovasc. Interv. 2008, 1:209-216.
57. Sahoo S.K., Labhasetwar V. Mol. Pharm. 2005, 2:373-383.
58. Medintz I.L., Uyeda H.T., Goldman E.R., Mattoussi H. Nat. Mater. 2005, 4:435-446.
59. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G., Wu A.M., Gambhir S.S., Weiss S. Science 2005, 307:538-544.
60. Lin Z., Ma Q., Fei X., Zhang H., Su X. Anal. Chim. Acta 2014, 818:54-60.